Active, not recruiting
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
NCT04817826
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Gastric Cancer, +10 more
- Locations
-
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan, Italy